Key Points
- Group Iv Gp Lp Column purchased 89,200 Eikon Therapeutics shares at an average price of $11.56, representing a transaction valued at approximately $1.03 million.
- Eikon shares were trading at $10.71, down 1.4%, while the company reported a quarterly loss of $1.63 per share—slightly worse than analysts’ $1.61 estimate.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and a $25 target price; Wedbush cut its target to $4 and maintained an “underperform” rating, while Cantor Fitzgerald reiterated “overweight.”
Eikon Therapeutics, Inc. (NASDAQ:EIKN - Get Free Report) major shareholder Group Iv Gp Lp Column acquired 89,200 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The stock was bought at an average price of $11.56 per share, with a total value of $1,031,152.00. Following the acquisition, the insider directly owned 89,200 shares of the company's stock, valued at $1,031,152. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Eikon Therapeutics Trading Down 1.4%
Shares of EIKN opened at $10.71 on Wednesday. Eikon Therapeutics, Inc. has a 1 year low of $7.90 and a 1 year high of $17.40. The stock has a market cap of $580.16 million and a P/E ratio of -2.62. The stock's 50-day moving average price is $10.55 and its two-hundred day moving average price is $10.88.
Eikon Therapeutics (NASDAQ:EIKN - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) EPS for the quarter, missing analysts' consensus estimates of ($1.61) by ($0.02). As a group, equities analysts forecast that Eikon Therapeutics, Inc. will post -7.24 EPS for the current year.
Hedge Funds Weigh In On Eikon Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its holdings in Eikon Therapeutics by 29.0% during the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company's stock worth $55,873,000 after buying an additional 962,046 shares during the period. Parkman Healthcare Partners LLC bought a new position in Eikon Therapeutics in the second quarter valued at approximately $3,341,000. Comprehensive Financial Management LLC bought a new position in Eikon Therapeutics in the second quarter valued at approximately $1,517,000. Citadel Advisors LLC acquired a new position in shares of Eikon Therapeutics in the second quarter valued at approximately $170,000. Finally, California State Teachers Retirement System acquired a new position in shares of Eikon Therapeutics in the second quarter valued at approximately $51,000.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. Wedbush lowered their target price on shares of Eikon Therapeutics from $5.00 to $4.00 and set an "underperform" rating for the company in a research note on Friday, August 14th. Weiss Ratings raised shares of Eikon Therapeutics from a "sell (e-)" rating to a "sell (e)" rating in a research report on Monday, August 3rd. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Eikon Therapeutics in a report on Friday, August 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $25.00.
Check Out Our Latest Report on EIKN
Eikon Therapeutics Company Profile
(
Get Free Report)
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
